GSK agreed to pay $110 million to secure rights to Hutchmed’s antibody-targeted therapy conjugate (ATTC) platform asset, characterized as a first-in-class approach combining targeted delivery with dual cancer-driving protein blockade. The deal covers an initial development plan for lung, colorectal, and pancreatic cancers. The acquisition provides GSK with a Phase 1-ready program and expands its oncology pipeline with a targeted modality designed for improved therapeutic index compared with conventional monotherapies. The transaction highlights how large pharma continues to buy differentiated payloads and platform-linked assets to accelerate oncology entry timelines.